ArticleJournal of thrombosis and thrombolysis2026
Association of lipid-lowering drugs with venous thromboembolism outcomes: a phenome-wide association study and a drug-target Mendelian randomization study.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Common anticoagulants can lead to potentially fatal internal bleeding, which restricts their extensive use in the prevention of Venous thromboembolism (VTE). We aimed to use a PheWAS and MR analysis to find novel therapeutic targets for VTE events(containing pulmonary embolism (PE) and deep vein thrombosis (DVT)) and offer new opportunities to develop safer and more effective preventative medications. The present study utilized a PheWAS analysis to examine 2005 health-related phenotypes from the MRC-IEU consortium on VTE risk genetic variants to pinpoint possible treatment targets. Subsequently, through Summary-data-based MR (SMR) and inverse-variance-weighted MR (IVW-MR) analysis, we assessed the associations between lipid-lowering drug targets (including HMGCR inhibitor, PCSK9 inhibitor, and NPC1L1 inhibitor) and VTE events. We utilized two types of genetic instruments to represent the exposure to lipid-lowering drugs: eQTLs of drug target genes and genetic variants within or near drug target genes associated with LDL cholesterol from genome-wide association studies. PheWAS analysis identified 13 cholesterol-related traits significantly associated with VTE risk, indicating lipid-lowering drugs might be targets of VTE outcomes. SMR analysis showed that higher NPC1L1 gene expression in the blood was a risk factor for PE (OR = 1.107, 95%CI = 1.026-1.195; p = 0.009). Additionally, an IVW-MR association was found between LDL mediated by NPC1L1 and blood clot in the lung (OR = 4.091, 95% CI = 1.375-12.173; p = 0.011). This study suggested a potential causal relationship between NPC1L1 inhibition and the reduced risk of PE.
Indexed as
Identifiers
40415139What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.